To this end, using two independent datasets, including 226 stage I–II adenocarcinomas of the National Cancer Center in Japan (NCC) and 230 stage I–IV adenocarcinomas of the cancer genome atlas (TCGA), we examined the relationship between KRT19 mRNA expression and the outcomes of lung adenocarcinoma patients. The gene discussed is KRT19; the disease is cancer.